However, most of this progress has been made in lung adenocarcinoma, through the identification of mutations of the epidermal growth factor receptor (EGFR), EML4-ALK fusions, and other driver alterations that are highly sensitive to targeted drug therapy. This evidence concerns the gene EGFR and lung adenocarcinoma.